Search Result

Results for "

EBV

" in MedChemExpress (MCE) Product Catalog:

By Targets:	EBV (41) Apoptosis (5) Autophagy (1) Bacterial (2) CMV (3) DNA/RNA Synthesis (2) Epoxide Hydrolase (2) Filovirus (1) Glucocorticoid Receptor (1) HBV (1) HDAC (1) Histone Methyltransferase (3) HIV (2) HIV Protease (3) HPV (1) HSV (8) IFNAR (1) Influenza Virus (2) Liposome (1) MHC (1) Nucleoside Antimetabolite/Analog (2) Parasite (1) Peptide-Drug Conjugates (PDCs) (2) Phosphatase (1) Proteasome (1) Proton Pump (2) Reactive Oxygen Species (ROS) (1) Reference Standards (4) Sirtuin (1)
By Research Areas:	Cancer (26) Cardiovascular Disease (1) Endocrinology (1) Infection (41) Inflammation/Immunology (15) Metabolic Disease (1) Neurological Disease (4)
Oligonucleotides:	Nucleoside Analogs (1) Uridine (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Antibodies

Oligonucleotides

Targets Recommended: EBV

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P10664

EBV EBNA3B (416-424)	EBV	Inflammation/Immunology
EBV EBNA3B (416-424) is an HLA-A11-restricted peptide antigen derived from EBV EBNA3B protein .

HY-P10497A

EBV BZLF1 (190-197) TFA	Bacterial	Infection Inflammation/Immunology
EBV BZLF1 (190-197) TFA is an immunodominant CEF-controlling peptide derived from Epstein-Barr virus (EBV). EBV BZLF1 (190-197) TFA is a suitable epitope for CD8+ T cells to stimulate the release of IFNg. CTL responses to EBV BZLF1 (190-197) TFA are diverse and cross-recognize similar peptides from both host self-proteins and bacterial proteins. EBV BZLF1 (190-197) TFA can be used to study autoimmune diseases .

HY-149577

EBV lytic cycle inducer-1	EBV	Cancer
Epstein-Barr virus (EBV) lytic cycle inducer-1 Dp44mT (compound C7) is an iron-chelatoe-like compound. Dp44mT cooperates with HDAC inhibitor Romidespin (HY-15149) and SAHA to induce *EBV* lytic cycle. Dp44mT reactivates *EBV* lytic cycle by activating the ERK1/2-autophagy axis in epithelial cancers .

HY-P10607

IALYLQQNW	EBV	Cancer
IALYLQQNW is a specific nonapeptide sequence derived from the tumor-associated antigen latent membrane protein 1 (LMP1) encoded by Epstein-Barr virus (EBV). As a latent T-cell epitope, IALYLQQNW is able to activate EBV-specific cytotoxic T lymphocytes (CTLs), which are able to recognize and kill EBV-infected cells expressing LMP1. IALYLQQNW plays an important role in the immune response against EBV-associated tumors and can be used in the study of Hodgkin's disease and nasopharyngeal carcinoma .

HY-N8459

α-Cembrenediol α-CBD	EBV	Cancer
α-Cembrenediol is a potent inhibitor of *EBV*.α-Cembrenediol inhibits the early antigen of the Epstein-Bar virus. α-Cembrenediol also has anti-tumour activity .

HY-175683

EBV-IN-1	EBV HIV	Infection
EBV-IN-1 (Compound 15) is an antiviral agent. EBV-IN-1 has a potent antiviral activity against EBV with a EC₅₀ of 0.17  μM. EBV-IN-1 also shows inhibitory effects on HIV (EC₅₀: 20.8 μM). EBV-IN-1 can be used for EBV and HIV infections research .

HY-P10497

EBV BZLF1 (190-197)	Bacterial	Infection Inflammation/Immunology
EBV BZLF1 (190-197) is an immunodominant CEF-controlling peptide derived from Epstein-Barr virus (EBV). EBV BZLF1 (190-197) is a suitable epitope for CD8+ T cells to stimulate the release of IFNg. CTL responses to EBV BZLF1 (190-197) are diverse and cross-recognize similar peptides from both host self-proteins and bacterial proteins. EBV BZLF1 (190-197) can be used to study autoimmune diseases .

HY-P10663

EBV EBNA3A (379-387)	EBV	Infection Inflammation/Immunology
EBV EBNA3A (379-387) is an antigenic epitope that may elicit the latent-specific CD8 ⁺ T cell response in HLA-B*07:02 ⁺ individuals .

HY-P1890

*CEF14, EBV* Rta Protein (28-37)**	EBV	Infection
CEF14, EBV Rta Protein (28-37) is the HLA A24-restricted epitope from Epstein-Barr Virus Rta protein (28-37).

HY-122486

Lophirachalcone Lophirochalcone	EBV	Cancer
Lophirachalcone (Lophirochalcone) is an inhibitor of the activation of EB virus (EBV) induced by tumor promoter teleocidin B-4. Lophirachalcone has antitumor activity .

HY-P11299

EBNA-1 (386–405 aa)	EBV	Infection Neurological Disease Inflammation/Immunology
EBNA-1 (386-405 aa) is a cross-reactive viral antigen peptide. EBNA-1 (386-405 aa) has a high molecular similarity to GlialCAM (370-389 aa) and it induces the production of cross-reactive antibodies that recognize both EBV antigens and glial cells in the central nervous system, thereby triggering autoimmune responses. EBNA-1 (386-405 aa) can used for Epstein-Barr virus (EBV) infection and multiple sclerosis (MS) research .

HY-131236

EBNA1-IN-SC7	EBV	Cancer
EBNA1-IN-SC7 (compound SC7) is a selective Epstein-Barr nuclear antigen 1 (EBNA1) inhibitor that interferes with EBNA1-DNA binding activity with an IC₅₀ value of 23 μM. EBNA1-IN-SC7 is used in EBV (Epstein-Barr virus)-related cancer research .

HY-B2117

Valpromide	Epoxide Hydrolase EBV	Infection Neurological Disease
Valpromide is an amide derivative of Valproic acid (HY-10585) and an orally active epoxide hydrolase inhibitor that can cross the blood-brain barrier. Valpromide has antiepileptic, anticonvulsant, and antipsychotic effects. Valpromide also exhibits antiviral activity and can inhibit the reactivation of the *EBV* lytic cycle .

HY-119098

GSK983	EBV HPV	Infection
GSK983 is a broad-spectrum antiviral agent. GSK983 inhibits the replication of adenovirus-5 (Ad-5) and polyoma virus SV40. GSK983 inhibits the growth of cell lines immortalized by EBV, HTLV1, HPV. GSK983 induces the expression of interferon-stimulated genes .

HY-120137

CMP-5	Histone Methyltransferase	Cancer
CMP-5 is a potent, specific, and selective PRMT5 inhibitor, while displays no activity against PRMT1, PRMT4, and PRMT7 enzymes. CMP-5 selectively blocks S2Me-H4R3 by inhibiting PRMT5 methyltransferase activity on histone preparations. CMP-5 prevents Epstein-Barr virus (EBV)-driven B-lymphocyte transformation but leaving normal B cells unaffected .

HY-113846A

CMP-5 dihydrochloride	Histone Methyltransferase	Cancer
CMP-5 dihydrochloride is a potent, specific, and selective PRMT5 inhibitor, while displays no activity against PRMT1, PRMT4, and PRMT7 enzymes. CMP-5 dihydrochloride selectively blocks S2Me-H4R3 by inhibiting PRMT5 methyltransferase activity on histone preparations. CMP-5 dihydrochloride prevents EBV-driven B-lymphocyte transformation but leaving normal B cells unaffected .

HY-113846

CMP-5 hydrochloride	Histone Methyltransferase	Cancer
CMP-5 hydrochloride is a potent, specific, and selective PRMT5 inhibitor, while displays no activity against PRMT1, PRMT4, and PRMT7 enzymes. CMP-5 hydrochloride selectively blocks S2Me-H4R3 by inhibiting PRMT5 methyltransferase activity on histone preparations. CMP-5 hydrochloride prevents EBV-driven B-lymphocyte transformation but leaving normal B cells unaffected .

HY-N9837

Methyl lucidenate L	EBV	Infection
Methyl lucidenate L is a natural triterpene acid methyl ester with inhibitory effects on EBV (Epstein-Barr virus) activation .

HY-N10024

Ganolactone Ganolactone A	EBV	Infection
Ganolactone is a triterpenoid compound. Ganolactone has a weak inhibitory effect on *EBV* early antigen .

HY-125471

VK-1727 1 Publications Verification	EBV	Infection Inflammation/Immunology Cancer
VK-1727 is a selective small molecule inhibitor of EBNA1. VK-1727 can reduce EBNA1 DNA binding activity. VK-1727 selectively blocks the proliferation and metabolic activity of EBV+ cells, instead of EBV- cells. VK-1727 is used in multiple sclerosis research .

HY-P10772

L2P4	Peptide-Drug Conjugates (PDCs) EBV	Cancer
L2P4 is a peptide-based and EBNA1 targeting fluorescent probe, which inhibits the EBNA1 homodimer formation and selectively inhibits EBV+ tumor growth. L2P4 exhibits cytotoxicity in EBV-positive C666-1 cell with LC₅₀ of 46.4 μM .

HY-P10772A

L2P4 TFA	Peptide-Drug Conjugates (PDCs) EBV	Cancer
L2P4 TFA is a peptide-based and EBNA1 targeting fluorescent probe, which inhibits the EBNA1 homodimer formation and selectively inhibits EBV+ tumor growth. L2P4 TFA exhibits cytotoxicity in EBV-positive C666-1 cell with LC₅₀ of 46.4 μM .

HY-130789

Cimigenol-3-one	EBV	Infection
Cimigenol-3-one inhibits Epstein-Barr virus early antigen (EBV-EA) activation .

HY-N11649

Methyl lucidenate Q	Others	Infection
Methyl lucidenate Q is a methyl lucidenate. Methyl lucidenate Q shows potent inhibitory effects on *EBV-EA* induction .

HY-122213

RU-25055	Glucocorticoid Receptor	Endocrinology
RU-25055 is a potent antiglucocorticoid. RU-25055 inhibits early antigen production of the EpsteinBarr virus (EBV) by dexamethasone .

HY-N11020

Cabenoside D	EBV	Infection Inflammation/Immunology
Cabenoside D (compound 8) is a triterpenoid glycoside, which can be isolated from the methanol extract of lichen root. Cabenoside D shows anti-inflammatory activity and inhibits inflammation induced by 12-O-tetracylacyl hormone-13-acetate (TPA) in mice. Cabenoside D also inhibits TPA-induced Epstein-Barr virus (EBV) early antigen (EBV-EA) activation .

HY-148170

L-I-OddU	EBV DNA/RNA Synthesis Nucleoside Antimetabolite/Analog	Infection
L-I-OddU, a L-5'-halo- dioxolane nucleoside analogue, is a potent and selective anti-Epstein-Barr virus (EBV) agent with an EC₅₀ value of 0.03μM. L-I-OddU has low cytotoxicity with a CC₅₀ value of 1000 nM. L-I-OddU has antiviral activity by suppressing replicative EBV DNA and viral protein synthesis .

HY-15489

Scriptaid 4 Publications Verification Scriptide; GCK1026	HDAC Autophagy Apoptosis Influenza Virus	Cancer
Scriptaid is a potent histone deacetylase (HDAC) inhibitor, used in cancer research. Scriptaid is also a sensitizer to antivirals and has potential for epstein-barr virus (EBV)-associated lymphomas treatment.

HY-N3254

Minumicrolin Murpanidin; (+)-Murpanidin	HSV EBV	Infection
Minumicrolin is a plant growth inhibitor. Minumicrolin can be isolated from Murraya paniculata. Minumicrolin inhibits Epstein-Barr virus early antigen (EBV-EA) activation .

HY-W725179

VK-2019	EBV	Cancer
VK-2019 is an oral active, selective EBNA1((Epstein-Barr Nuclear Antigen 1) inhibitor and can be used for study of EBV-associated carcinomas .

HY-16305

Maribavir Maximum Cited Publications 12 Publications Verification 1263W94; BW1263W94; GW257406X	EBV CMV	Infection
Maribavir is a potent inhibitor of histone phosphorylation catalyzed by wild-type pUL97 in vitro, with an IC₅₀ of 3 nM. Maribavir has potent antiviral activity against HCMV and Epstein-Barr virus (EBV).

HY-N15402

Porritoxin	EBV	Infection
Porritoxin (compound 1 ) is a metabolite of Alternaria porri. Porritoxin shows the inhibitory effect on Epstein-Barr virus early antigen (EBV-EA) activation induced by TPA (HY-18739) .

HY-N8873

Silychristin B	Others	Cancer
Silychristin B is an antitumor promoter. Silychristin B inhibits TPA induced Epstein-Barr virus early antigen (EBV-EA) induction. Silychristin B can be isolated from milk thistle .

HY-U00224

BRL44385	EBV HSV	Infection
BRL44385 is a potent and selective inhibitor of the replication of herpes simplex virus types 1 and 2 (HSV-1 and HSV2), varicella zoster virus (VZV) and Epstein-Barr virus (EBV).

HY-N15758

Amorphispironone	EBV	Cancer
Amorphispironone (Compound 1) is a rotenoid that can be isolated the leaves of A. fruticosa. Amorphispironone exhibits remarkable inhibitory effects on *EBV-EA* activation induced by TPA. Amorphispironone exhibits potent anti-tumor-promotion activity on mouse skin tumor promotion in vivo .

HY-N13710

20-Hydroxylucidenic acid E2	EBV	Infection Cancer
20-Hydroxylucidenic acid E2 is a triterpenoid compound found in Ganoderma lucidum. It exhibits significant inhibitory effects on inflammation induced by TPA (HY-18739). Additionally, 20-Hydroxylucidenic acid E2 can suppress the expression of EBV early antigen induced by TPA (HY-18739), with a IC₅₀ of 290 mol ratio/32 pmol TPA (meaning that when the molar concentration of this compound is 290 times that of 32 pmol of TPA, it can inhibit 50% of EBV early antigen expression). Therefore, 20-Hydroxylucidenic acid E2 has potential applications in anti-inflammatory and anticancer research .

HY-N11009

11-Oxomogroside II A1	EBV	Infection
11-Oxomogroside II A1 (compound 7) is an oxidized cucurbitin. It can be isolated from the ethanol extract of Rohanberry fruit. 11-Oxomogroside II A1 inhibits the activation of Epstein-Barr virus (EBV) early antigen (EBV-EA) induced by 12-O-tetradecanoylphorbol-13-acetate (TPA). 11-Oxomogroside II A1 also weakly inhibits the activation of (±)-(E)-methyl-2-[(E)-hydroxyimino]-5-nitro-6-methoxy-3-hexemide (NOR 1), a nitric oxide (NO) donor .

HY-138096

Z-LLF-CHO Z-Leu-Leu-Phe-CHO	Proteasome	Cancer
Z-LLF-CHO (Z-Leu-Leu-Phe-CHO) is a potent inhibitor of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex (K_i = 460 nM). Z-LLF-CHO is also a NF-κB nuclear translocation inhibitor .

HY-N8041

Mogroside III A2	HSV	Infection
Mogroside III A2 is a cucurbitane glycoside. Mogroside III A2 can inhibit Epstein-Barr virus early antigen (EBV-EA) activation. Mogroside III A2 shows weak inhibitory effects on activation of NOR 1 .

HY-16305R

Maribavir (Standard) 1263W94 (Standard); BW1263W94 (Standard); GW257406X (Standard)	EBV Reference Standards CMV	Infection
Maribavir (Standard) is the analytical standard of Maribavir. This product is intended for research and analytical applications. Maribavir is a potent inhibitor of histone phosphorylation catalyzed by wild-type pUL97 in vitro, with an IC₅₀ of 3 nM. Maribavir has potent antiviral activity against HCMV and Epstein-Barr virus (EBV).

HY-N6033

Ferruginol (+)-Ferruginol	EBV HSV Apoptosis	Infection Cardiovascular Disease Neurological Disease Cancer
Ferruginol ((+)-Ferruginol), a natural diterpenoid, is an inhibitor of the activation of Epstein-Barr virus early antigen (EBV-EA). Ferruginol inhibits the growth of thyroid cancer cells through the induction of mitochondrial apoptosis. Ferruginol has antitumor, cardioprotective, antioxidant, gastroprotective, and neuroprotective activities .

HY-N2006

Ganoderic acid B	EBV HIV Protease	Infection Inflammation/Immunology
Ganoderic acid B is a triterpene isolated from a mushroom Ganoderma lucidum. Ganoderic acid B inhibits the activation of Epstein-Barr virus (EBV) antigens as telomerase inhibitor. Ganoderic acid B is a moderately active inhibitor against HIV-1 protease (IC₅₀: 170 μM) .

HY-170547

DNA polymerase-IN-6	DNA/RNA Synthesis HSV Filovirus	Infection
DNA polymerase-IN-6 (Compound 27) exhibits inhibitory activity against DNA polymerase, and inhibits HCMV, HSV-1, HSV-2 and *EBV* with EC₅₀s of 0.33, 1.9, 0.76 and 0.066 µM, respectively .

HY-P1911

CEF27, Epstein-Barr Virus BRLF-1 lytic (148-156)	EBV	Infection
CEF27, Epstein-Barr Virus BRLF-1 lytic 148-156 corresponding to amino acids 148-156 of the BRLF1 protein. BRLF1 is a transcriptional activator that binds directly to a GC-rich motif present in some Epstein-Barr virus (EBV) lytic gene promoters .

HY-N12978

Benzyl β-gentiobioside	Others	Cancer
Benzyl β-gentiobioside is a phenyl alcohol glycoside found in peach kernels (Prunus persica seeds). Benzyl β-gentiobioside has anti-tumor promoting activity by inhibiting TPA (12-O-tetradecanoylphorbol 13-acetate, a tumor promoter)-induced Epstein-Barr virus early antigen (EBV-EA) activation .

HY-N7691

3,29-O-Dibenzoyloxykarounidiol Karounidiol dibenzoate	EBV	Infection Cancer
3,29-O-Dibenzoyloxykarounidiol (Karounidiol dibenzoate) is a triterpene benzoate isolated from the fruit of Momordica grosvenori. 3,29-O-Dibenzoyloxykarounidiol has potent inhibitory effects on Epstein-Barr virus early antigen (EBV-EA) induced by tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) .

HY-133108

Azadirachtin B	EBV Parasite Phosphatase Influenza Virus	Infection Metabolic Disease Inflammation/Immunology Cancer
Azadirachtin B is an limonoid isolated from seed kernels of Azadirachta indica. Azadirachtin B increases alkaline phosphatase (ALP) activity and stimulates osteoblast differentiation. Azadirachtin B is active against the Epstein-Barr virus early antigen (EBV-EA). Azadirachtin B has insecticidal, nematocidal, anticancer, anti-inflammatory, antiviral and osteogenic properties .

HY-169480

Lipid C2	Liposome	Infection Cancer
Lipid C2 is an ionizable cationic lipid that has been used in the formation of lipid nanoparticles (LNP) for mRNA delivery in vivo. LNPs containing Lipid C2 and encapsulating an mRNA reporter selectively accumulate in the liver and spleen but not the heart, lungs, or kidneys in mice. LNP containing Lipid C2 and encapsulating mRNA encoding the Epstein-Barr virus (EBV) protein latent membrane protein 2 (LMP-2), in combination with an anti-programmed cell death protein 1 (PD-1) antibody, decrease tumor volume and reverse T cell exhaustion, as well as increase the percentage of CD3 ⁺CD8 ⁺ central and CD3 ⁺CD8 ⁺ effector memory T cells and decrease the percentage of CD3 ⁺ T cells expressing Pd-1, in the spleen in a CT26 murine EBV-infected colon cancer model .

HY-P5470

LMP2A (426-434)	EBV IFNAR	Inflammation/Immunology
LMP2A (426-434) is a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope of Epstein-Barr virus (EBV) latent membrane protein 2A (LMP2A). LMP2A (426-434) can trigger an immune response in individuals expressing different HLA-A02 subtypes (A02:01, A02:03, A02:06 and A02:07). LMP2A (426-434) can induce a strong IFN-γ* secretion response, stimulating the production of a high proportion of CD8 ⁺ IFN-γ ⁺ T cells. LMP2A (426-434) induces specific CTLs to effectively kill target cells expressing LMP2A. LMP2A (426-434) can be used to study EBV-related malignant tumors (such as Hodgkin's disease and nasopharyngeal carcinoma) .

HY-N2006R

Ganoderic acid B (Standard)	EBV Reference Standards HIV Protease	Infection Inflammation/Immunology
Ganoderic acid B (Standard) is the analytical standard of Ganoderic acid B. This product is intended for research and analytical applications. Ganoderic acid B is a triterpene isolated from a mushroom Ganoderma lucidum. Ganoderic acid B inhibits the activation of Epstein-Barr virus (EBV) antigens as telomerase inhibitor. Ganoderic acid B is a moderately active inhibitor against HIV-1 protease (IC₅₀: 170 μM) .

Cat. No.	Product Name	Target	Research Area

HY-P10664

EBV EBNA3B (416-424)	EBV	Inflammation/Immunology
EBV EBNA3B (416-424) is an HLA-A11-restricted peptide antigen derived from EBV EBNA3B protein .

HY-P10497A

EBV BZLF1 (190-197) TFA	Bacterial	Infection Inflammation/Immunology
EBV BZLF1 (190-197) TFA is an immunodominant CEF-controlling peptide derived from Epstein-Barr virus (EBV). EBV BZLF1 (190-197) TFA is a suitable epitope for CD8+ T cells to stimulate the release of IFNg. CTL responses to EBV BZLF1 (190-197) TFA are diverse and cross-recognize similar peptides from both host self-proteins and bacterial proteins. EBV BZLF1 (190-197) TFA can be used to study autoimmune diseases .

HY-P10607

IALYLQQNW	EBV	Cancer
IALYLQQNW is a specific nonapeptide sequence derived from the tumor-associated antigen latent membrane protein 1 (LMP1) encoded by Epstein-Barr virus (EBV). As a latent T-cell epitope, IALYLQQNW is able to activate EBV-specific cytotoxic T lymphocytes (CTLs), which are able to recognize and kill EBV-infected cells expressing LMP1. IALYLQQNW plays an important role in the immune response against EBV-associated tumors and can be used in the study of Hodgkin's disease and nasopharyngeal carcinoma .

HY-P10772A

L2P4 TFA	Peptide-Drug Conjugates (PDCs) EBV	Cancer
L2P4 TFA is a peptide-based and EBNA1 targeting fluorescent probe, which inhibits the EBNA1 homodimer formation and selectively inhibits EBV+ tumor growth. L2P4 TFA exhibits cytotoxicity in EBV-positive C666-1 cell with LC₅₀ of 46.4 μM .

HY-P10497

EBV BZLF1 (190-197)	Bacterial	Infection Inflammation/Immunology
EBV BZLF1 (190-197) is an immunodominant CEF-controlling peptide derived from Epstein-Barr virus (EBV). EBV BZLF1 (190-197) is a suitable epitope for CD8+ T cells to stimulate the release of IFNg. CTL responses to EBV BZLF1 (190-197) are diverse and cross-recognize similar peptides from both host self-proteins and bacterial proteins. EBV BZLF1 (190-197) can be used to study autoimmune diseases .

HY-P10663

EBV EBNA3A (379-387)	EBV	Infection Inflammation/Immunology
EBV EBNA3A (379-387) is an antigenic epitope that may elicit the latent-specific CD8 ⁺ T cell response in HLA-B*07:02 ⁺ individuals .

HY-P10662

*HLA-B0801-binding EBV peptide**	Peptides	Infection Inflammation/Immunology
HLA-B0801-binding EBV* peptide is an Epstein-Barr virus (EBV) epitope FLRGRAYGL. HLA-B0801-binding EBV* peptide can bind to the HLA-B0801 molecule. HLA-B0801-binding EBV peptide can be presented to CD8+ T cells through HLA-B*0801 to activate a specific immune response .

HY-P1890

*CEF14, EBV* Rta Protein (28-37)**	EBV	Infection
CEF14, EBV Rta Protein (28-37) is the HLA A24-restricted epitope from Epstein-Barr Virus Rta protein (28-37).

HY-P11299

EBNA-1 (386–405 aa)	EBV	Infection Neurological Disease Inflammation/Immunology
EBNA-1 (386-405 aa) is a cross-reactive viral antigen peptide. EBNA-1 (386-405 aa) has a high molecular similarity to GlialCAM (370-389 aa) and it induces the production of cross-reactive antibodies that recognize both EBV antigens and glial cells in the central nervous system, thereby triggering autoimmune responses. EBNA-1 (386-405 aa) can used for Epstein-Barr virus (EBV) infection and multiple sclerosis (MS) research .

HY-P10772

L2P4	Peptide-Drug Conjugates (PDCs) EBV	Cancer
L2P4 is a peptide-based and EBNA1 targeting fluorescent probe, which inhibits the EBNA1 homodimer formation and selectively inhibits EBV+ tumor growth. L2P4 exhibits cytotoxicity in EBV-positive C666-1 cell with LC₅₀ of 46.4 μM .

HY-138096

Z-LLF-CHO Z-Leu-Leu-Phe-CHO	Proteasome	Cancer
Z-LLF-CHO (Z-Leu-Leu-Phe-CHO) is a potent inhibitor of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex (K_i = 460 nM). Z-LLF-CHO is also a NF-κB nuclear translocation inhibitor .

HY-P1911

CEF27, Epstein-Barr Virus BRLF-1 lytic (148-156)	EBV	Infection
CEF27, Epstein-Barr Virus BRLF-1 lytic 148-156 corresponding to amino acids 148-156 of the BRLF1 protein. BRLF1 is a transcriptional activator that binds directly to a GC-rich motif present in some Epstein-Barr virus (EBV) lytic gene promoters .

HY-P5470

LMP2A (426-434)	EBV IFNAR	Inflammation/Immunology
LMP2A (426-434) is a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope of Epstein-Barr virus (EBV) latent membrane protein 2A (LMP2A). LMP2A (426-434) can trigger an immune response in individuals expressing different HLA-A02 subtypes (A02:01, A02:03, A02:06 and A02:07). LMP2A (426-434) can induce a strong IFN-γ* secretion response, stimulating the production of a high proportion of CD8 ⁺ IFN-γ ⁺ T cells. LMP2A (426-434) induces specific CTLs to effectively kill target cells expressing LMP2A. LMP2A (426-434) can be used to study EBV-related malignant tumors (such as Hodgkin's disease and nasopharyngeal carcinoma) .

HY-P1920

CEF19, Epstein-Barr Virus latent NA-3A (458-466)	EBV	Inflammation/Immunology
CEF19, Epstein-Barr Virus latent NA-3A (458-466) is a single peptide epitope, YPLHEQHGM, representing residues 458-466 of the type 1 Epstein-Barr Virus (EBV) nuclear antigen 3A protein (B95.8 strain). CEF19, Epstein-Barr Virus latent NA-3A (458-466) can significantly affect cytotoxic T-lymphocyte (CTL) recognition .

Cat. No.	Product Name	Target	Research Area

HY-P990189

Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243)	MHC Apoptosis Reactive Oxygen Species (ROS)	Infection Cancer
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to monkey/human MHC class II. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) can inhibits tumor cells proliferation and induce apoptosis. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) increases cellular reactive oxygen species (ROS) and loss of mitochondrial membrane potential in human endothelial cells. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) can be used for the researches of cancer and infection, such as lymphoma .

Species:	Human (12) Mouse (1)
Tag:	His (12) Tag Free (1) Avi (9)
Source:	HEK293 (12) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P72890

	CD21 Protein, Human (HEK293, His) Complement receptor type 2; Cr2; EBV receptor; CD21; C3DR	Human	HEK293
	CD21 Protein, a receptor for complement C3, Epstein-Barr virus, and HNRNPU, activates B lymphocytes and aids Epstein-Barr virus entry in microbial infection. Its engagement with these ligands highlights its vital role in immune responses and interactions, regulating B-cell activation and host defense against infections. CD21 Protein, Human (HEK293, His) is the recombinant human-derived CD21 protein, expressed by HEK293 , with C-His, C-10*His labeled tag.

HY-P705352

	*HLA-A11:01&B2M&EBV(AVFDRKSDAK) Monomer Protein, Human (Biotinylated, HEK293, His-Avi)** HLA-A1101 & B2M & EBV* (AVFDRKSDAK)	Human	HEK293

HY-P705305

	*HLA-A02:01&B2M&EBV EBNA(FMVFLQTHI) Monomer Protein, Human (Biotinylated, HEK293, His-Avi)** HLA-A0201 & B2M & EBV* EBNA (FMVFLQTHI)	Human	HEK293

HY-P705307

	*HLA-A02:01&B2M&EBV LMP1(YLLEMLWRL) Monomer Protein, Human (Biotinylated, HEK293, His-Avi)** HLA-A0201 & B2M & EBV* LMP1 (YLLEMLWRL)	Human	HEK293

HY-P705308

	*HLA-A02:01&B2M&EBV LMP2(FLYALALLL) Monomer Protein, Human (Biotinylated, HEK293, His-Avi)** HLA-A0201 & B2M & EBV* LMP2 (FLYALALLL)	Human	HEK293

HY-P705353

	*HLA-A11:01&B2M&EBV LMP2(SSCSSCPLSK) Monomer Protein, Human (Biotinylated, HEK293, His-Avi)** HLA-A1101 & B2M & EBV* LMP2 (SSCSSCPLSK)	Human	HEK293

HY-P705306

	*HLA-A02:01&B2M&EBV EBNA3C(LLDFVRFMGV) Monomer Protein, Human (Biotinylated, HEK293, His-Avi)** HLA-A0201 & B2M & EBV* EBNA3C (LLDFVRFMGV)	Human	HEK293

HY-P705309

	*HLA-A02:01&B2M&EBV LMP2A(CLGGLLTMV) Monomer Protein, Human (Biotinylated, HEK293, His-Avi)** HLA-A0201 & B2M & EBV* LMP2A (CLGGLLTMV)	Human	HEK293

HY-P705360

	*HLA-A24:02&B2M&EBV EBNA3A(RYSIFFDYM) Monomer Protein, Human (Biotinylated, HEK293, His-Avi)** HLA-A2402 & B2M & EBV* EBNA3A (RYSIFFDYM)	Human	HEK293

HY-P705361

	*HLA-A24:02&B2M&EBV EBNA3B(TYSAGIVQI) Monomer Protein, Human (Biotinylated, HEK293, His-Avi)** HLA-A2402 & B2M & EBV* EBNA3B (TYSAGIVQI)	Human	HEK293

HY-P77602

	CD21 Protein, Mouse (HEK293, His) EBV receptor; CD21; C3DR; CR2; C3DRSLEB9; CVID7; SLEB9	Mouse	HEK293
	CD21 protein, as a receptor for complement C3d and HNRNPU, plays a crucial role in B lymphocyte activation. It forms complexes with CD19, CR2/CD21, CD81 and IFITM1/CD225 and contributes to immune responses. CD21 Protein, Mouse (HEK293, His) is the recombinant mouse-derived CD21 protein, expressed by HEK293 , with C-His labeled tag.

HY-P700118AF

	Animal-Free IL-27 beta/EBI3 Protein, Human (His) Interleukin-27 subunit alpha; IL-27-A; Interleukin-27 subunit beta; IL-27B; Epstein-Barr virus-in_x0002_duced gene 3 protein; EBV-induced gene 3 protein; EBI3; p28; Interleukin-30; IL-30	Human	E. coli
	The IL-27 beta/EBI3 protein binds to IL27 to form IL-27 interleukin, which is critical in innate immunity. IL-27 has both pro- and anti-inflammatory properties, regulating T helper cell development, inhibiting T cell proliferation, stimulating cytotoxic T cell activity, inducing B cell isotype switching, and affecting innate immune cells. Animal-Free IL-27 beta/EBI3 Protein, Human (His) is the recombinant human-derived animal-FreeIL-27 beta/EBI3 protein, expressed by E. coli , with C-His labeled tag. This product is for cell culture use only.

HY-P704232

	CCR7/CD197 Protein-VLP, Human (HEK293) BLR2; L CC-CKR-7; L CCR-7; L CD197; L CDw197; L CMKBR7; L EBI1; LC-C chemokine receptor type 7; LEpstein-Barr virus-induced G-protein coupled receptor 1 (EBI1; L EBV-induced G-protein coupled receptor 1); LMIP-3 beta receptor	Human	HEK293
	CCR7/CD197 Protein-VLP, Human (HEK293) is the recombinant human-derived CCR7/CD197 protein, expressed by HEK293, with tag free tag. Formed in HEK293 cultures, these VLPs concentrate membrane proteins on the cell surface, producing high-concentration proteins ideal for immunization and antibody screening. Given the high immunogenicity of VLPs, the immunization protocol such as antigen dose, schedule, and adjuvant, requires optimization. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P705433.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81562

	CD21 Antibody (YA1307) C3DR antibody; CD 21 antibody; CD21 antibody; Complement C3d receptor antibody; Complement component (3d/Epstein Barr virus) receptor 2 antibody; Complement receptor type 2 antibody; CR antibody; Cr2 antibody; CR2_HUMAN antibody; CVID7 antibody; EBV receptor antibody; EBV-R antibody; Epstein Barr virus receptor antibody; Epstein-Barr virus receptor antibody; EVBR antibody; SLEB9 antibody;	WB, IHC-P, ICC/IF, IP, FC, IF-Tissue	Human, Mouse, Rat
	CD21 Antibody (YA1307) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD21.

HY-P81143

	CCR7 Antibody 1 Publications Verification CCR7_HUMAN; BLR 2; BLR2; C C chemokine receptor type 7; C C CKR 7; CC chemokine receptor 7; CC chemokine receptor type 7; CC CKR 7; CCCKR7; CCR 7; CD 197; CD197; CD197 antigen; CDW197; Chemokine C C motif receptor 7; Chemokine C C receptor 7; Chemokine receptor 7-like protein; EBI 1; EBI1; Ebi1h; EBV Induced G Protein Coupled Receptor 1; Epstein Barr virus induced G protein coupled receptor; Epstein Barr virus induced gene 1; EVI 1; EVI1; Lymphocyte Specific G Protein Coupled Peptide Receptor; MGC108519; MIP 3 beta receptor; MIP3 Beta Receptor.	WB, IHC-P, ICC/IF, ELISA	Human, Mouse, Rat
	CCR7 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to CCR7.

HY-P86464

	CD21 Antibody (YA6156) CR2; C3DR; Complement receptor type 2; Cr2; Complement C3d receptor; Epstein-Barr virus receptor; EBV receptor; CD21	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	CD21 Antibody (YA6156) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD21.

HY-P82947

	EBI3 Antibody (YA2692) EBI3; IL27B; Interleukin-27 subunit beta; IL-27 subunit beta; IL-27B; Epstein-Barr virus-induced gene 3 protein; EBV-induced gene 3 protein	WB	Human, Mouse, Rat
	EBI3 Antibody (YA2692) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to EBI3.

HY-P87313

	TRAF1 Antibody (YA6996) 4732496E14Rik antibody; EBI6 antibody; EBV induced protein 6 antibody; Epstein-Barr virus-induced protein 6 antibody; MGC:10353 antibody; Tnf receptor associated factor 1 antibody; TNF receptor-associated factor 1 antibody; TRAF 1 antibody; TRAF1 antibody; TRAF1_HUMAN antibody	WB, IP	Human, Rat
	TRAF1 Antibody (YA6996) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to TRAF1.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-148170

L-I-OddU		Nucleoside Analogs Uridine
L-I-OddU, a L-5'-halo- dioxolane nucleoside analogue, is a potent and selective anti-Epstein-Barr virus (EBV) agent with an EC₅₀ value of 0.03μM. L-I-OddU has low cytotoxicity with a CC₅₀ value of 1000 nM. L-I-OddU has antiviral activity by suppressing replicative EBV DNA and viral protein synthesis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

EBV

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Antibodies

Oligonucleotides

Natural
Products